Epidemiology and Antifungal Susceptibility of Bloodstream Fungal Isolates in Pediatric Patients: a Spanish Multicenter Prospective Survey
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Data on fungemia epidemiology and antifungal susceptibility of isolates from children are scarce, leading frequently to pediatric empirical treatment based on available adult data. The present study was designed to update the epidemiological, mycological, and in vitro susceptibility data on fungal isolates from children with fungemia in Spain. All fungemia episodes were identified prospectively by blood culture over 13 months at 30 hospitals. Tests of susceptibility to amphotericin B, flucytosine, fluconazole, itraconazole, posaconazole, voriconazole, anidulafungin, caspofungin, and micafungin were performed at participant institutions by a microdilution colorimetric method. New species-specific clinical breakpoints for fluconazole, voriconazole, and echinocandins were also applied. A total of 203 episodes of fungemia in 200 children were identified. A higher proportion of fungal isolates was from general wards than intensive care units (ICU). Candida parapsilosis (46.8%), Candida albicans (36.5%), Candida tropicalis (5.9%), Candida glabrata (3.9%), and Candida guilliermondii (2.5%) were the leading species. C. parapsilosis was the predominant species except in neonates. C. albicans was the most frequent in neonatal ICU settings (51.9%). Intravascular catheter (79.3%), surgery (35%), prematurity (30%), and neutropenia (11%) were the most frequent predisposing factors. Most Candida isolates (95.1%) were susceptible to all antifungals. When the new species-specific clinical breakpoints were applied, all C. parapsilosis isolates were susceptible to echinocandins except one, which was micafungin resistant. This is the largest published series of fungemia episodes in the pediatric setting. C. parapsilosis is the most prevalent species in Spain, followed by C. albicans and C. tropicalis . Resistance to azole and echinocandin agents is extremely rare among Candida species. The fluconazole resistance rate in Spain has decreased in the last 10 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 2×
“The incidence of bloodstream fungal infection, in adults and pediatric patients, has risen in the last decade as a result of a combination of several factors, such as increased use of central venous catheters, extensive use of parenteral nutrition, mucosa alteration or prolonged neutropenia due to more aggressive anti…”
BackgroundEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 2×
“The incidence of bloodstream fungal infection, in adults and pediatric patients, has risen in the last decade as a result of a combination of several factors, such as increased use of central venous catheters, extensive use of parenteral nutrition, mucosa alteration or prolonged neutropenia due to more aggressive anti…”
BackgroundPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 1×
“krusei are very infrequent in the pediatric setting (2, 3, 10, 12, 14, 22, 23, 26), fluconazole is still a reasonable option for fungemia treatment before species identification, except in children with prior azole exposure, as is recommended by the latest guidelines published (7, 11).”
BackgroundEpidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Neofytos, D., Horn, D., Anaissie, E., Steinbach, W., Olyaei, A., Fishman, J., Pfaller, M., Chang, C., Webster, K., & Marr, K. (2009) · Clinical Infectious Diseases · doi:10.1086/595846 · Cited by 801 · cited 1×
“The incidence of bloodstream fungal infection, in adults and pediatric patients, has risen in the last decade as a result of a combination of several factors, such as increased use of central venous catheters, extensive use of parenteral nutrition, mucosa alteration or prolonged neutropenia due to more aggressive anti…”
BackgroundTortorano, A. M., Peman, J., Bernhardt, H., Klingspor, L., Kibbler, C. C., Faure, O., Biraghi, E., Canton, E., Zimmermann, K., Seaton, S., et al. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1103-y · Cited by 509 · cited 2×
“The incidence of bloodstream fungal infection, in adults and pediatric patients, has risen in the last decade as a result of a combination of several factors, such as increased use of central venous catheters, extensive use of parenteral nutrition, mucosa alteration or prolonged neutropenia due to more aggressive anti…”
BackgroundPfaller, M. A., Andes, D., Diekema, D. J., Espinel-Ingroff, A., & Sheehan, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.09.002 · Cited by 314 · cited 2×
“Applying the new species-specific clinical breakpoints for fluconazole, voriconazole, and echinocandins (5, 15, 16, 19), the resistance rates were equal to those obtained by applying the CLSI breakpoints (4), except for C.”
ResultNational Surveillance of Fungemia in Denmark (2004 to 2009)
Arendrup, M. C., Bruun, B., Christensen, J. J., Fuursted, K., Johansen, H. K., Kjældgaard, P., Knudsen, J. D., Kristensen, L., Møller, J., Nielsen, L., et al. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.01811-10 · Cited by 223
Pfaller, M. A., Andes, D., Arendrup, M. C., Diekema, D. J., Espinel-Ingroff, A., Alexander, B. D., Brown, S. D., Chaturvedi, V., Fowler, C. L., Ghannoum, M. A., et al. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.03.002 · Cited by 130 · cited 2×
“Applying the new species-specific clinical breakpoints for fluconazole, voriconazole, and echinocandins (5, 15, 16, 19), the resistance rates were equal to those obtained by applying the CLSI breakpoints (4), except for C.”
Result
Cited by
Global trends in the distribution of Candida species causing candidemia
Guinea, J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12539 · Cited by 680
Self-citationEpidemiology and risk factors for invasive candidiasis
Yapar, N. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s40160 · Cited by 610
“parapsilosis.(20,21,61) Likewise, in another Mediterranean country, Italy, C.”
Puig-Asensio, M., Padilla, B., Garnacho-Montero, J., Zaragoza, O., Aguado, J. M., Zaragoza, R., Montejo, M., Muñoz, P., Ruiz-Camps, I., Cuenca-Estrella, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12380 · Cited by 299
Candida parapsilosis Is a Significant Neonatal Pathogen: A Systematic Review and Meta-analysis
Pammi, M., Holland, L., Butler, G., Gacser, A., & Bliss, J. M. (2013) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3182863a1c · Cited by 206
Metadata
- Authors
- Pemán, J., Cantón, E., Linares-Sicilia, M. J., Roselló, E. M., Borrell, N., Ruiz-Pérez-de-Pipaon, M. T., Guinea, J., García, J., Porras, A., García-Tapia, A. M., Pérez-del-Molino, L., Suárez, A., Alcoba, J., & García-García, I.
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2011-12
- Volume
- 49
- Issue
- 12
- Pages
- 4158-4163
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W2148779922
- Cited by
- 75
- References
- 9
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.